Osaic Holdings
ACRV icon

Osaic Holdings’s Acrivon Therapeutics ACRV Stock Holding History

Osaic Holdings’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-5,080
Closed -$29.5K – 7392
2024
Q2 		$29.5K Hold
5,080
– – ﹤0.01% 5068
2024
Q1 		$36.3K Buy
+5,080
New +$23.6K ﹤0.01% 4960

Other funds holding ACRV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Osaic Holdings's ACRV Position: Q3 2024 in Review

Osaic Holdings sold out of Acrivon Therapeutics (ACRV) in Q3 2024, closing a stake of 5,080 shares — an estimated $29.5K sold.

Osaic Holdings first reported a position in ACRV in Q1 2024 and held it in 2 quarters. The position peaked at $36.3K in Q1 2024. 55 funds tracked by Wall St. Rank hold ACRV as of Q3 2024.

  • Osaic Holdings reported no remaining Acrivon Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Osaic Holdings sold 5,080 Acrivon Therapeutics shares in Q3 2024, an estimated $29.5K.
  • Osaic Holdings first reported a position in Acrivon Therapeutics in Q1 2024 and held it in 2 quarters.
  • Osaic Holdings's Acrivon Therapeutics position peaked at $36.3K in Q1 2024.
  • 55 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2024.

Based on Osaic Holdings's 13F filing for Q3 2024, filed 13 Nov 2024.